- Data on AXL as a therapeutic target in lung cancers to be highlighted at AACR -

- Ph1a/2b 1L STK11m NSCLC trial design to be outlined at ELCC -

BERGEN, Norway, March 28,2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Company will be presenting three posters at two upcoming scientific conferences: ESMO's European Lung Cancer Congress (ELCC) 2023 and the American Association for Cancer Research (AACR) Annual Meeting 2023.

European Lung Cancer Conference 2023

March 29 - April 1, 2023

Bella Center - Copenhagen, Denmark

Poster Title: Phase 1b/2a safety and tolerability study of bemcentinib with pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or metastatic non-squamous NSCLC with/without STK11 mutations (https://cslide.ctimeetingtech.com/elcc23hybrid/attendee/confcal/presentation/list?q=78TiP)

Session Title: Poster Display session (ID 51)

Session Date & Time: Friday March 31, 2023, 12:00 PM - 12:45 PM

Location: Exhibition and Poster area

Presentation Number: 78TiP

American Association for Cancer Research Annual Meeting 2023

April 14 - 19, 2023

Orlando County Convention Center - Orlando, Florida

Poster Title: AXL as a Therapeutic Target in STK11 mutant NSCL (https://www.abstractsonline.com/pp8/#!/10828/presentation/3138)C 
Session Title: Combination Immunotherapies 1 
Session Date and Time: Monday Apr 17, 2023, 1:30 PM - 5:00 PM 
Location: Section 39 
Poster Board Number: 18 
Abstract Presentation Number: 3245 

Poster Title:  Combined inhibition of AXL and ATR enhances replication stress, cell death and immune response in small cell lung cancer (https://www.abstractsonline.com/pp8/#!/10828/presentation/1853) 
Session Title:  DNA Repair / Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes 
Session Date and Time: Wednesday Apr 19, 2023, 9:00 AM - 12:30 PM 
Location: Section 18 
Poster Board Number: 8 
Abstract Presentation Number: 6206 

The posters from both conferences will be available on the Company's website in the Scientific Presentations (https://www.bergenbio.com/investors/presentations/) portion of the Investors section following their presentations.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA 

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA 

rune.skeie@bergenbio.com

Investor Relations / Media Relations 

Graham Morrell 

graham.morrell@bergenbio.com

Media Relations Norway

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA 

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19. 

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com  

Forward looking statements 

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.